Skip to main content
Clinical Trials/NCT00901212
NCT00901212
Completed
Phase 4

Evaluation fo Resynchronization Therapy for Heart Failure (EARTH)

Montreal Heart Institute11 sites in 1 country120 target enrollmentOctober 2003
ConditionsHeart Failure

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Montreal Heart Institute
Enrollment
120
Locations
11
Primary Endpoint
The primary endpoint is total exercise duration at a constant submaximal load (ETT submaximal load is defined as 75% of peak exercise during the baseline metabolic evaluation)
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

Heart failure is a major health problem in Canada. Recent advances in medical and device therapy have helped to reduce the morbidity and mortality of patients with this problem. Among these treatments, cardiac resynchronization therapy (CRT) has very recently been shown to be effective to improve functional class, quality of life and exercise tolerance of the patients with the most severe symptoms of heart failure and a prolonged duration of the QRS on the 12-lead Electrocardiography (ECG).

Detailed Description

Resynchronization of the failing ventricle is currently achieved by pacing the left and right ventricles simultaneously with specialized electrodes and a cardiac stimulator. However, controversy persists concerning the optimal configuration for cardiac pacing in these patients. Right ventricular pacing alone has been shown to be deleterious in some patient populations. The benefits of biventricular pacing in heart failure patients may be due primarily to left ventricular stimulation and may, in some patients, be decreased by the presence of simultaneous RV stimulation. Preliminary data from our own animal work suggest that in the majority of cases, LV stimulation alone is better than RV stimulation, and that BiV stimulation represents an intermediary situation between LV and RV stimulation.

Registry
clinicaltrials.gov
Start Date
October 2003
End Date
February 2010
Last Updated
13 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Montreal Heart Institute
Responsible Party
Principal Investigator
Principal Investigator

Bernard Thibault

MD

Montreal Heart Institute

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patient must have answered "NO" to all of the exclusion criteria
  • Does the patient have:
  • Indication for permanent ventricular pacing?
  • Chronotropic insufficiency?
  • Second or third degree AV block, either persistent or intermittent?
  • A pacemaker or an ICD which is paced in ventricular chamber more than 5% of the time?
  • Does the patient have a reversible cause of LV dysfunction such as post-partum cardiomyopathy, tachycardia induced cardiomyopathy, acute myocarditis or acute toxic cardiomyopathy (including acute alcoholic)?
  • Did the patient have myocardial infarction or cardiac surgery in the 6 weeks preceding the pre-implant visit?
  • Does the patient have a moderate or severe cardiac valve stenosis?
  • Is the patient's capacity to walk is limited by reasons other than heart failure symptoms (e.g., angina, intermittent claudication, severe lung condition or arthritis)?

Outcomes

Primary Outcomes

The primary endpoint is total exercise duration at a constant submaximal load (ETT submaximal load is defined as 75% of peak exercise during the baseline metabolic evaluation)

Time Frame: one year

Secondary Outcomes

  • Clinical, electrical, echocardiographic, MUGA scan endpoints, Neuro-hormones(one year)

Study Sites (11)

Loading locations...

Similar Trials